RNA Therapy: The Next Nig Thing after mAbs?
Will RNA therapies follow in the footsteps of monoclonal antibodies as
the next major development for the biopharmaceutical industry? Advances
have been made, along with some setbacks – but ultimately the issue
of delivery will be the single greatest challenge.
By Giles Somers at Datamonitor (September 2009)
Keywords: sales growth, success, mAbs, RNA therapy, monoclonal antibodies,